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Abstract
Background: The aim of this study is to investigate the effects of a radio electric asymmetric treatment on
psycho-physiological disorders (PPD). PPD are often stress related and are under the unconscious control of the
patient and cannot be traced back to any serious physical disease. The brain stimulation treatment protocol used is
called Neuro Psycho Physical Optimization (NPPO) with a Radio Electric Asymmetric Conveyer (REAC) device.
Methods: Psychological stress and PPD were measured for a group of 888 subjects using the Psychological Stress
Measure (PSM) test, a self-administered questionnaire. Data were collected immediately before and after the 4-
weeks of REAC treatment cycle.
Results: This study showed a significant reduction in scores measuring subjective perceptions of stress for subjects
treated with a cycle of NPPO REAC treatment. At the end-point the number of subjects reporting symptoms of
stress-related PPD on the PSM test was significantly reduced, whereas in the placebo group the difference was not
significant.
Conclusion: A cycle of NPPO treatment with REAC was shown to reduce subjective perceptions of stress
measured by the PSM test and in particular on PPD.
Trial Registration: This trial has been registered in the Australian New Zealand Clinical Trials Registry (ANZCTR)
with the number: ACTRN12607000463471.
Background
A high proportion of patients with general distress were
suffering only from PPD (also known as “Psychosomatic
disorders” or “maladaptive illness”) classified as “psycho-
logical factors affecting medical condition” in the Diag-
nostic and Statistical Manual of Mental Disorders
(DSM-IV-TR, APA, 2000) (code 777). PPD are charac-
terized by psychological and physical symptoms that are
caused by stress and emotional factors and involve one
o more systems.
The physiological changes involved are those that nor-
mally are related with specific emotional states, but in
PPD these changes are more intense and sustained.
Common PPD include insomnia, temporal-mandibular
joint problems (in particular joint pain), migraine head-
aches, tension headaches, attention deficit and hyperac-
tivity disorder (ADHD), arthritis, functional diarrhea,
ulcerative colitis, essential hypertension, asthma and pri-
mary dysmenorrhoea. These symptoms are often medi-
cally unexplained [1,2] and often difficult to treat. The
p u r p o s eo ft h i sw o r ki st ov e r i f yi ft h eu s eo fN P P O
REAC treatment was effective in reducing subjective
perceptions of stress as measured by a validated ques-
tionnaire, the PSM test [3,4]. This questionnaire allows
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any medium, provided the original work is properly cited.to classify the stress-level and the stress-related symp-
toms of PPD [5] of the subjects.
Methods and Materials
The study was performed in accordance with the
Declaration of Helsinki, with the Società di Ottimizza-
zione Neuro Psico Fisica e CRM Terapia’s institutional
ethics committee approval, and all subjects provided
written informed consent.
Participants
888 subjects were included in the study from an initial
group of 1453 of patients who attended the Rinaldi-Fon-
tani Institute in Florence, Italy (Additional file 1). These
patients showed different types of stress-related PPD
such as tension and migraine headaches, essential hyper-
tension, anxious tremors, colitis, irritable bowel syn-
drome, bruxism, neck and back pain, chronic pain
syndrome, bronchial asthma, peptic ulcer disease, skin
disorders and insomnia. Subjects were not taking any
psychotropic medication.
Sample size and randomization
This is a naturalistic study therefore patients, with any
type of stress-related pathology, came spontaneously to
our medical centre and were observed in the normal
clinical practice.
In order to have a group of control for comparing the
results from the treated patients, two groups were cre-
ated. Therefore, subjects were randomly selected for
each group with a simple computerized randomization
by an external operator. and were divided into 2 groups:
Group A subjects receiving active treatment and Group
B subjects receiving placebo treatment in a specific
room.
Even if this study took place in Italy with Italian inves-
tigators, we could not find an Italian registry in the
World Health Organization - International Clinical
Trials Registry Platform http://www.who.int/ictrp/net-
work/primary/en/index.html. Therefore we decided to
select the first in the list that was the Australian New
Zealand Clinical Trial Registry (ANZCTR) and regis-
tered (n° ACTRN12607000463471).
Demographic characteristics
Group A included 688 subjects: 401 (58,28%) females,
average age 42.3 ± 11.3 yrs, and 287 (41,71%) males,
average age 41.1 ± 11.4 yrs. These patients were treated
with a cycle of NPPO of “active” REAC. Group B
included 200 subjects: 123(61,5%) females, average age
48.8 ± 19.4 yrs, and 77 (38,5%) males, average age 45.8
± 18.5 yrs. These patients were treated with a cycle of
NPPO of “Placebo” REAC. Table 1.
Psychological test and psychiatric assessment
The Psychological Stress Measure (PSM) [3,4,6] was
specifically developed to detect the stress levels in non-
clinical population. The PSM is usually a 49 items self-
report paper and pencil questionnaire; but in this study
we used an electronic version to collect and process the
data, and to analyze the results. Each item is based on
clusters of stress conditions: loss of self-control, irritabil-
ity, psycho-physiological disorders, confusion, anxiety,
depression, physical pain, hyperactivity and agitation.
Patients were asked to answer the questions about their
psychological stress using a 4-points scale to describe
the intensity of their condition (very much = 4, much =
3, little = 2, none = 1). The final score is expressed in
Total Points (TP). Furthermore, in order to detect the
presence of the PPD symptoms, scores obtained from
items hearing voices that other people do not hear (16),
feeling afraid to go out of your house alone (25), your
feelings being easily hurt (34), nausea or upset stomach
(40) were specifically used. Both groups of subjects were
clinically evaluated at t0 (before treatment) and t1 (after
treatment) by a psychiatrist. At baseline and in the total
of the sample, the mainly psychiatric diagnosis (accord-
ing with DSMIV-TR) have been “subthreshold” forms of
Generalized Anxiety Disorder (N = 557 patients) and
Anxiety Disorder Not Otherwise Specified (NOS) (N =
114). After the treatment, all the symptoms of these
mild clinical conditions have shown a remarkable
improvement. In the remaining 217 subjects non rele-
vant clinical aspect has been detected.
Six-hundred-eighty-eight subjects (average PSM test
total scores 122.53 ± 6.75) were treated with NPPO
REAC therapy; 200 (average PSM test total scores
122.96 ± 7.041) were treated with “placebo NPPO
REAC” and used as control.
Description of the REAC and of the brain stimulation
treatment protocol NPPO
The REAC is an innovative medical device [7,8] aimed
to promote a reduction of the dysfunctional modifica-
tions in the Nervous System induced by stress and
Table 1 Demographic characteristics
Group A Group B Total
Sex
Female 401 (58,28%) 123 (62%) 688 (100%) (A)
Male 287 (41,71%) 77 (%39) 200 (100%) (B)
Age
N 688 200 888
Mean 41,8 47,7 43,13
SD 11,35 19,14 13,71
Table legend text. Demographic characteristics.
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articles [9-20]. The REAC brain stimulation protocol
treatment consists in a cycle of 18 NPPO sessions,
applied in specific points of the auricular pavilion [10].
The REAC treatment is simple, rapid, non-invasive and
applied without pain. The instrument that we used is
registered under the trademark Convogliatore di
Radianza Modulante - CRM by ASMED, Italy.
Statistical analysis
Statistical analysis was performed using the Number
Needed to Treat Analysis (NNT) Table 2. For compar-
ing total points before and after the treatment (placebo),
the Wilcoxon Signed Rank Test was used (Additional
file 2and 3) while the McNemar (Additional file 4and 5)
test analyzed the presence of the PPD symptoms. Test,
and all results P < 0.05 has been considered statistically
significant.
Results
Before the “active” treatment among 688 subjects, 512
(74.41%) were positive for stress-related psycho physio-
logical disorder (PPD), and in the 200 patients of the
“placebo” group these kind of disorders were detected in
150 (75%) subjects.
After “active” REAC-treatment, only 138 of 512
patients (26.9%) still presented symptoms of stress-
related PPD (McNemar Test Chi-Square = 372,003,
Asymp. Sig. = 0,000). In terms of percentage, migraine
headache and bronchial asthma still remains in about
65% and 30% of these “poor-responder” subjects, respec-
tively, whereas in the “placebo” group, a wider spectrum
of symptoms (mainly migraine headaches, essential
hypertension, anxious tremors, neck and back pain,
chronic pain, insomnia, etc) were observed in 148 of
150 subjects (98.6%).
In Group A, the TP scores decreased significantly
from 122.3 to 96.01, Figure 1 (Wilcoxon Signed Rank
Test Z = -22,735, Asymp. Sig (2-tailed) = 0,000); in
Group B, the decrease of TP scores from 122.96 to
122.11, was not statistically significant (Wilcoxon Signed
Rank Test Z=-0,914, Asymp. Sig (2-tailed) = 0,361), Fig-
ure 2, Table 3.
There is no significant correlation between the results
of the PSM total points before/after Therapy and the
age or the gender (Additional file 6).
Discussion
This study is the evolution in longitudinal terms of a
previous study, and it is specifically targeted to assess
each one stress-related clusters of PSM test.
Table 2 NNT analysis
Present Absent Total
Given (Group A) 138 550 688
Not Given (Group B) 148 52 200
Total 286 602 888
Risk of Outcome in Treated Group: 0,2000
Risk of Outcome in Control Group: 0,7400
Absolute Risk Reduction: 0,5400
Relative Risk: 0,2700
Relative Risk Reduction 0,7300
Number Needed To Treat 1,8500
Table legend text. Number Needed to Treat Analysis.
Figure 1 Box Plot Graphs (treated). Box Plot Graphs of the PSM
total points of the real treatment.
Figure 2 Box Plot Graphs (placebo). Box Plot Graphs of the PSM
total points of the placebo.
Rinaldi et al. Health and Quality of Life Outcomes 2011, 9:54
http://www.hqlo.com/content/9/1/54
Page 3 of 5Recent literature data showed that the medical use of
electricity, in many kinds of applications, is probably
one of the most important alternative to the “typical”
psychopharmacological strategies in the management of
Mental Disorders, included the stress-related PPD [21].
As pointed out Bruce S. McEwen, the brain is the key
organ of the adaptive and maladaptive responses to
stress [22] because it determines what is threatening
and, therefore, potentially stressful, as well as initiating
the behavioral, as well as many of the physiological
responses to the stressors, which can be either adaptive
or damaging [23-25]. All the adaptations are also
expressed by changes of brain electrical activity. All neu-
rological functions are governed mainly by two neuro-
transmitters: the excitatory glutamate and inhibitory
gamma amino butyric acid - (GABA). Their release
depends on the electrical changes due to ion flows. The
REAC, with its exclusive high technology, reshapes these
flows. This induces a progressive, stable and successful
reorganization of the bioelectric activity of the central
nervous system and consequently of the alterated sys-
tems and functions due to PPD in our body. We call
this reorganization Neuro Psycho Physical Optimization
[9-11,13-20].
Conclusions
This research highlights the efficacy of NPPO treatment
with REAC on PPD cluster of PSM test in non psychia-
tric subjects. These conditions represent the most com-
prehensive mental suffering in the general population.
Further studies are needed to verify the stability over
time when using more than one cycle, although it could
be very difficult to obtain and to maintain a selected
group, especially after treatment. Our results showed
that NPPO treatment with REAC will help to speed up
the physiological capability of the organism recovery,
optimising the adaptive response to environmental stres-
sors and contributing to the elimination of dysfunctional
adaptive responses like PPD.
Clearly, our research presents several limitations. First,
the wide variation and polymorphism of the stress-related
symptomatology need to be considered in the global evalua-
tion of our results. Second, it should be considered that
REAC treatment is an innovative treatment and these
patients could have had great expectations. Third, its
administration is almost imperceptible and this characteris-
tic can be the basis of the very little placebo effect. Fourth,
the different mean age between the Group A and Group B
could somehow conditioning the obtained results: therefore,
there will be more reliable results comparing similar groups
of age. Finally, a longer period of observation and the
administration of further REAC-therapy cycles are neces-
sary to assess the stability of our goals over time.
Additional material
Additional file 1: CONSORT Checklist. Consort checklist.
Additional file 2: Statistic of Real therapy 688. Statistic of Real therapy
688 (Group A)
Additional file 3: Statistic of Placebo control 200. Statistic of Placebo
control 200 (Group B)
Additional file 4: Statistic of Real therapy 688. McNemar Test of Real
Therapy (Group A)
Additional file 5: Statistic of Placebo control 200. McNemar Test of
Placebo control (Group B)
Additional file 6: Statistic of Real therapy 688. Correlation between
PSM Total points and subgroups (age and gender)
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